Lung Cancer Considered

As part of IASLC’s ongoing series of podcasts in world languages, Dr. Alfredo Addeo moderates a Virtual Tumor Board discussion with Dr. Andrea Fillipi and Dr. Piergiorgio Solli. The tumor board focuses on the management of resectable EGFR-mutant NSCLC.

Host: • Alfredo Addeo, MD
Head of Oncology Service
University Hospital Geneva

Guests:
Andrea R. Filippi, MD
Head of Radiation Oncology, Fondazione Istituto Nazionale dei Tumori, Milan
Associate Professor, Radiation Therapy
Department of Oncology, University of Milan

Piergiorgio Solli, MD, PhD
Head of Thoracic Surgery
IRCCS Fondazione Istituto Nazionale dei Tumori, Milan

As part of IASLC’s ongoing series of podcasts in world languages, Dr. Alfredo Addeo moderates a Virtual Tumor Board discussion with Dr. Andrea Fillipi and Dr. Piergiorgio Solli. The tumor board focuses on the management of resectable EGFR-mutant NSCLC.
Guest Name(s) & Title(s):

Host:
Alfredo Addeo, MD
Head of Oncology Service
University Hospital Geneva

Andrea R. Filippi, MD ([email protected])
Head of Radiation Oncology, Fondazione Istituto Nazionale dei Tumori, Milan
Associate Professor, Radiation Therapy
Department of Oncology, University of Milan
X: @AndrearicFili
LinkedIn: https://www.linkedin.com/in/andrea-r-filippi-94a459211/

Piergiorgio Solli, MD, PhD ([email protected])
Head of Thoracic Surgery
IRCCS Fondazione Istituto Nazionale dei Tumori, Milan
X: @PiergiorgioSoll
Instagram: https://www.instagram.com/sollipiergiorgio/
LinkedIn: https://www.linkedin.com/in/piergiorgio-solli-b1b85a73/

In this episode of Lung Cancer Considered, host Dr. Stephen Liu discusses KRAS updates from the American Association for Cancer Research (AACR) 2026 Annual Meeting with Dr. Deborah Doroshow, Dr. David S. Hong, and Dr. Jonathan Riess.

Guests:

Deborah Doroshow, MD, PhD
Associate Professor of Medicine, Hematology/Oncology
Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai

David S. Hong, MD
Douglas E. Johnson Endowed Professor
Deputy Chair, Department of Investigational Cancer Therapeutics [A Phase I Program]
Division of Cancer Medicine
Clinical Medical Director, Clinical and Translational Research Center
The University of Texas MD Anderson Cancer Center

Jonathan Riess, MD
Associate Professor of Medicine, UC Davis Comprehensive Cancer Center
Director of Thoracic Oncology, University of California, Davis

This episode of Lung Cancer Considered, part of IASLC’s World Language Series, features host Dr. Narjust Florez leading a Spanish-language discussion with Dr. José Corona-Cruz and Dr. Diego Carrillo on perioperative chemoimmunotherapy in early-stage lung cancer. Using a real-world case, they explore clinical decision-making, biomarker considerations, and surgical challenges, with a focus on implementation barriers in Latin America. The conversation highlights multidisciplinary strategies and practical insights to optimize care in resource-variable settings.

This episode of LCC covers the work of our nursing and allied health professional committee and, most importantly, highlight their role in the care of patients with thoracic malignancies.

Guests:

Professor Nicole Kiss is a Fellow of Dietitians Australia and Clinical Associate Professor in the Institute for Physical Activity and Nutrition at Deakin University. Nicole co-leads the Exercise and Nutrition for Cancer research group, with her research focused on early identification of cancer-related muscle loss and improving access to treatment.

Dr. Morten Quist is a former IASLC Board member and is currently an Associate Professor and Research Physiotherapist at the University Hospital of Copenhagen, Rigshospitalet. For the past 25 years, he has pioneered clinical exercise-based rehabilitation for people living with cancer, with a primary focus on exercise, prehabilitation, and rehabilitation in lung cancer. His work bridges research, clinical care, patient advocacy, and voluntary engagement – always with patient wellbeing at the center.